Citations

Mayo Clinic

Showing 10 of 108537 citations.

Applicability of individualized metabolic surgery score for prediction of diabetes remission after endoscopic sleeve gastroplasty
Gala, Khushboo , Brunaldi, Vitor , Ghusn, Wissam , Vargas, Eric J. , Storm, Andrew C. , Acosta, Andrés , Dayyeh, Barham K. Abu

Therapeutic Advances in Gastrointestinal Endoscopy | April 26, 2024 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/26317745241247175 | PMID 38682042 Get It

Background: Endoscopic sleeve gastroplasty (ESG) is a safe and effective obesity treatment. The individualized metabolic score (IMS) is a validated score that uses preoperative variables predicting T2D remission (DR) in bariatric surgery. Objectives: We evaluated the applicability of using the IMS score to predict DR in patients after ESG. Design/Methods: We performed a retrospective review of patients with obesity and T2D who underwent ESG. We calculated DR, IMS score, and severity, and divided patients based on IMS category. Results: The cohort comprised 20 patients: 25% (5) mild, 55% (11) moderate, and 20% (4) severe IMS stages. DR was achieved in 60%, 45.5%, and 0% of patients with mild, moderate, and severe IMS scores ( p = 0.08), respectively. IMS score was significantly associated with DR ( p = 0.03), with the area under the curve of the receiver operating characteristic for predicting DR 0.85. Conclusion: These pilot data demonstrate that the IMS score appears to be useful in predicting DR after ESG.
Delayed targeted atelectasis in a case of bronchoscopic lung volume reduction with endobronchial valves
Chandra, Nikitha C , Fernandez-Bussy, Isabel , Walsh, Katherine, Walsh, Katherine L, Abia‐Trujillo, David

BMJ Case Reports | April 26, 2024 | Volume: 17 | Issue: 4 | Pages: e256573

10.1136/bcr-2023-256573 | PMID 38670566 Get It

A woman in her late 60s with severe chronic obstructive pulmonary disease (COPD) and emphysema underwent bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBV) to address hyperinflation. The initial EBV placement has led to partial lobar atelectasis of the left lower lobe and resulted in significant improvement in the patient’s symptoms and lung function. However, valve migration occurred later due to pneumothorax unrelated to valves, leading to suboptimal clinical improvement. The patient achieved delayed full lobar atelectasis 21 months after EBV placement, which led to a significant clinical improvement. The patient decided to be delisted from the lung transplant list due to the improvement. This case highlights the importance of considering delayed atelectasis as a possible outcome of EBV placement and suggests the need for further exploration of the long-term implications and associations of this procedure.
Radiographical bony lesions after discontinuation of immunosuppressant therapy: bone involvement in sarcoidosis
Pullins, Christopher, Varghese, Cyril , Koneru, S, Bracamonte, Jesse D., Pullins, Christopher

BMJ Case Reports | April 26, 2024 | Volume: 17 | Issue: 4 | Pages: e255611

10.1136/bcr-2023-255611 | PMID 38670568 Get It

We describe a patient who had failed renal transplant after 13 years, eventually requiring a graft nephrectomy and discontinuation of immunosuppressive therapy, including antithymocyte globulin, tacrolimus and mycophenolate while on steroid avoidance protocol. Within a few months of complete discontinuation of the immunosuppressive medications, she developed lower back pain associated with numbness in her right anterolateral thigh. The radiological imaging demonstrated multiple bony lesions throughout her axial and appendicular skeleton with normal pulmonary findings. A computerised tomography-guided bone biopsy from the left iliac crest revealed fragments of bone with granulomatous inflammation, thus making the diagnosis of extrapulmonary sarcoidosis. Initiating treatment with prednisone resulted in near-complete resolution of symptoms. Long-term immunosuppressive therapy is administered to all renal transplant recipients to help prevent acute rejection and loss of renal allograft. This case highlights that immunosuppressants can conceal the presence of underlying conditions in transplant patients.
Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine
Whitaker, David , Dumkrieger, Gina , Hentz, Joseph G. , Whitaker, David J , Dumkrieger, Gina , Dodick, David W. , Schwedt, Todd J.

Cephalalgia | April 25, 2024 | Volume: 44 | Issue: 4 | Pages: No page available

10.1177/03331024241249747 | PMID 38663902 Get It

Objective While a substantial body of research describes the disabling impacts of migraine attacks, less research has described the impacts of migraine on physical functioning between migraine attacks. The objective of this study is to describe physical impairment during and between migraine attacks as a dimension of burden experienced by people living with chronic migraine. Methods The physical impairment domain of the Migraine Physical Function Impact Diary was recorded in headache diaries from the Medication Overuse Treatment Strategy trial. Days with moderate to severe headache were used to approximate migraine attacks. Factor analysis and regression analysis were used to describe associations between migraine and physical impairment. Results 77,662 headache diary entries from 720 participants were analyzed, including 25,414 days with moderate to severe headache, 19,149 days with mild headache, and 33,099 days with no headache. Mean physical impairment score was 41.5 (SD = 26.1) on days with moderate to severe headache, 12.8 (SD = 15.0) on days with mild headache, and 5.2 (SD = 13.1) on days with no headache. Physical impairment on days with mild headache and days with no headache was significantly associated with days since last moderate to severe headache, physical impairment with last moderate to severe headache, mild headache (compared to no headache), depression, hypersensitivities and cranial autonomic symptoms. Conclusions Physical impairment occurs on migraine and non-migraine days. Study participants with frequent headaches, symptoms of depression, hypersensitivities and cranial autonomic symptoms experience physical impairment at a higher rate on days with no headache and days with mild headache. Clinical Trial Registration: ClinicalTrials.gov (NCT02764320)
The role of vascularized bone grafting for scaphoid nonunions in adolescents
Israel, Jacqueline S. , Pulos, Nicholas , Pulos, Nicholas , Bishop, Allen T. , Shin, Alexander Y.

Journal of Hand Surgery (European Volume) | April 25, 2024 | Volume: 49 | Issue: 9 | Pages: 1157-1159

10.1177/17531934241247279 | PMID 38663874 Get It

A total of 26 adolescent patients were treated for scaphoid nonunion with a vascularized bone graft from either the medial femoral condyle or dorsal distal radius. There was an 85% union incidence, improved carpal alignment and a low incidence of complications.
OSLD nanoDot characterization for carbon radiotherapy dosimetry
Taylor, Paige A. , Hartzell, Shannon , Ciocca, Mario , Magro, Giuseppe , Alvarez, P , Peeler, C , Howell, Rebecca M. , Taylor, Paige , Mirandola, Alfredo , Peterson, Christine B. , Koay, Eugene J. , Kry, Stephen F.

Physics in Medicine & Biology | April 25, 2024 | Volume: 69 | Issue: 11 | Pages: 115001

10.1088/1361-6560/ad43ac | PMID 38663410 Get It

Abstract Objective . This study characterized optically-stimulated luminescent dosimeter (OSLD) nanoDots for use in a therapeutic carbon beam using the Imaging and Radiation Oncology Core (IROC) framework for remote output verification. Approach . The absorbed dose correction factors for OSLD (fading, linearity, beam quality, angularity, and depletion), as defined by AAPM TG 191, were characterized for carbon beams. For the various correction factors, the effect of linear energy transfer (LET) was examined by characterizing in both a low and high LET setting. Main results . Fading was not statistically different between reference photons and carbon, nor between low and high LET beams; thus, the standard IROC-defined exponential function could be used to characterize fading. Dose linearity was characterized with a linear fit; while low and high LET carbon linearity was different, these differences were small and could be rolled into the uncertainty budget if using a single linearity correction. A linear fit between beam quality and dose-averaged LET was determined. The OSLD response at various angles of incidence was not statistically different, thus a correction factor need not be applied. There was a difference in depletion between low and high LET irradiations in a primary carbon beam, but this difference was small over the standard five readings. The largest uncertainty associated with the use of OSLDs in carbon was because of the k Q correction factor, with an uncertainty of 6.0%. The overall uncertainty budget was 6.3% for standard irradiation conditions. Significance . OSLD nanoDot response was characterized in a therapeutic carbon beam. The uncertainty was larger than for traditional photon applications. These findings enable the use of OSLDs for carbon absorbed dose measurements, but with less accuracy than conventional OSLD audit programs.
The Acute Abdomen: A Case-based Survival Guide to What the Surgeon Wants to Know
Kirby, John , Horst, Kelly K. , Boyum, James H. , Froemming, Adam T. , Khandelwal, Ashish , Kirby, John W , Froemming, Adam T , Khandelwal, Ashish , Horst, Kelly , Thiels, Cornelius A.

RadioGraphics | April 25, 2024 | Volume: 44 | Issue: 5 | Pages: No page available

10.1148/rg.230161 | PMID 38662589 Get It

Echocardiographic findings in cancer-associated non-bacterial thrombotic endocarditis: clinical series of 111 patients from a single institution
Kurmann, Reto , Klarich, Kyle W. , Wysokinska, Ewa , Kamińska, Alicja , Patrzałek, Patryk , Hodge, David O. , Wysokiński, Waldemar E. , Kurmann, Reto D, Houghton, Damon, Patrzalek, Patryk, Hodge, David, Wysokinski, Waldemar , Houghton, Damon E.

European Heart Journal - Cardiovascular Imaging | April 25, 2024 | Volume: 25 | Issue: 9 | Pages: 1255-1263

10.1093/ehjci/jeae112 | PMID 38662461 Get It

Abstract Aims Echocardiographic assessment of cancer-associated non-bacterial thrombotic endocarditis (Ca-NBTE) is limited to case reports and small clinical series. The study aimed to identify heart valve abnormalities and its relation to embolic complications and cancer types. Methods and results Manual review of echocardiographic images and medical records of Mayo Clinic patients (31 March 2002–30 June 2022) was performed. Ca-NBTE in 111 patients (mean age 63.2 ± 9.7 years, 66.7% female) predominantly affected mitral valves (MV) (69), 56 aortic (AV), 8 tricuspid (TV), and rarely pulmonic (PV) (1). In 18 patients, 2 valves were involved, 3 and 4 valve involvement in only a single patient each. Embolic complications were prevalent (n = 102, 91.9%). Ca-NBTE affected MV more frequently on the upstream (atrial) (90% vs. 49.3%) and TV downstream (ventricular) side (75% vs. 37.5%). NBTE size (cm) varied significantly among valves, with TV hosting the largest masses (0.63–2.40 × 0.39–1.77), compared with MV [(0.11–1.81 × 0.11–1.62), (length P = 0.001; width P = 0.03)] and AV [(0.20–2.70 × 0.11–1.51), (length P = 0.001; width P = 0.056)]; MV masses were borderline longer in systemic compared with cerebral emboli (P = 0.057). Majority of MV (79.6%) and AV (69.6%) had thickened leaflets. NBTE lesions commonly affected closing margins (73.9% MV, 85.7% AV, and 62.5% of TV) but rarely commissures of MV (8.7%), yet fairly frequently of AV (41.1%). Five patients had severe regurgitation of MV and 5 AV. Conclusion Ca-NBTE manifests mainly as thrombotic mobile masses attached to thickened MV and AV, with distinct variations in size based on valve type. Embolic destination but not cancer type is associated with NBTE mass size and location.
The Modified Reactive Strength Index Is a Valid Measure of Lower-Body Explosiveness in Male and Female High School Athletes
Witte, Brandon C., Schouten, Tyler C., Westphal, Jessica A., VanZile, Adam W., Jones, Daniel D., Widenhoefer, Tricia L., Dobbs, Ward C. , Luedke, Joel, Luedke, Joel A, Jones, Daniel D., Jagim, Andrew R. , Almonroeder, Thomas Gus

Journal of Strength & Conditioning Research | April 25, 2024 | Volume: 38 | Issue: 8 | Pages: 1428-1432

10.1519/jsc.0000000000004806 | PMID 38662946 Get It

Abstract Witte, BC, Schouten, TC, Westphal, JA, VanZile, AW, Jones, DD, Widenhoefer, TL, Dobbs, WC, Jagim, AR, Luedke, JA, and Almonroeder, TG. The modified reactive strength index is a valid measure of lower-body explosiveness in male and female high school athletes. J Strength Cond Res 38(8): 1428–1432, 2024—The modified reactive strength index (mRSI) is a commonly used metric to quantify lower-body explosiveness during countermovement jump (CMJ) performance. However, few studies have attempted to examine its validity as a measure of explosiveness, particularly among high school athletes. The purpose of this study was to examine the validity of the mRSI as a measure of lower-body explosiveness among a relatively large sample of male and female high school athletes from various sports. As part of this study, male ( n = 132) and female ( n = 43) high school athletes performed CMJs, while ground reaction forces were recorded using a force platform. The vertical ground reaction force data collected during the CMJs were used to derive the following variables: peak force (PF), peak power, time to PF, time to take-off, peak rate of force development, and the mRSI. Principal component analysis was applied and reduced these variables into 2 components related to “force” and “speed.” The mRSI loaded on both the force (loading = 0.82) and speed (loading = −0.46) components, indicating that it incorporates elements of both force and speed, although it loaded more strongly on the force component than the speed component. The observed pattern of cross-loading suggests that the mRSI is generally a valid measure of lower-body explosiveness for male and female high school athletes.
A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors
Seetharam, ­Mahesh , Norman, Aurora, Allred, Jacob B., Kong, Jianping , Lou, Yanyan , Dy, Grace K. , Weroha, S. John , Hendrickson, Andrea E. Wahner , Adjei, Alex A. , Allred, Jacob, Weroha, John, Wahner-Hendrickson, Andrea, Opyrchal, Mateusz , Wee, Wen , Mahipal, Amit , Reid, Joel M.

No container title available | April 25, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4261257/v1 | PMID 38746220 Get It

Abstract Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine is synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT). Methods: In this single arm multicohort phase I trial, we evaluated the safety and efficacy of Ribociclib plus Gemcitabine in patients with advanced solid tumors. Patients received Gemcitabine intravenously on days 1 and 8 followed by Ribociclib days 8–14, with treatment repeated every 3 weeks. Results: The study enrolled 43 patients between October 2017 and September 2019. The escalation phase (19 patients) determined the MTD and recommended phase II dose (RP2D) to be ribociclib 800mg daily and gemcitabine 1000mg/m2 for the expansion phase (24 patients). One patient experienced Grade 4 thrombocytopenia. Eleven patients experienced Grade 3 adverse events (AE), the most common being neutropenia, thrombocytopenia, and anemia. No partial or complete responses were observed. 15/22 (68%) of efficacy evaluable patients who received the MTD achieved best response of stable disease. Conclusions: The addition of Ribociclib to Gemcitabine was tolerated well and yielded stability of tumors in both cohorts. Ribociclib and gemcitabine could have synergistic activity in certain tumor types, and our data provides support for the combination. Clinical Trial Registration: NCT03237390